827
Views
29
CrossRef citations to date
0
Altmetric
Review

Multidrug-resistant Candida auris: an epidemiological review

&
Pages 551-562 | Received 21 Jan 2020, Accepted 30 Mar 2020, Published online: 13 Apr 2020

References

  • Centers for Disease Control and Prevention (CDC) Global emergence of invasive infections caused by the multidrug-resistant yeast Candida auris. [cited 2019 Dec 20]; Available from: https://www.cdc.gov/fungal/diseases/candidiasis/candida-auris-alert.html.
  • Lockhart SR, Etienne KA, Vallabhaneni S, et al. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis. 2017;64:134–140.
  • Osei SJ. Candida auris: A systematic review and meta-analysis of current updates on an emerging multidrug-resistant pathogen. Microbiology open. 2018;7:e00578.
  • Chowdhary A, Sharma C, Meis JF. Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. PLOS Pathog. 2017;13:e1006290.
  • Lone SA, Ahmad A. Candida auris-the growing menace to global health. Mycoses. 2019;62:620–637.
  • Meis JF, Chowdhary A. Candida auris—“Ten years after. J Fungi. 2019;6:2.
  • Satoh K, Makimura K, Hasumi Y, et al. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol. 2009;53:41–44.
  • Kim M, Shin JH, Sung H, et al. Candida haemulonii and Closely Related Species at 5 University Hospitals in Korea: identification, antifungal susceptibility, and clinical features. Clin Infect Dis. 2009;48:e57–61.
  • Lee WG, Shin JH, Uh Y, et al. First three reported cases of nosocomial fungemia caused by Candida auris. J Clin Microbiol. 2011;49:3139–3142.
  • Ong CW, Chen SC‐A, Clark JE, et al. Diagnosis, management and prevention of Candida auris in hospitals: position statement of the Australasian Society for Infectious Diseases. Intern Med J. 2019;49:1229–1243.
  • Ben-Ami R, Berman J, Novikov A, et al. Multidrug-resistant candida haemulonii and C. auris, tel aviv, Israel. Emerg Infect Dis. 2017;23:195–203.
  • Emara M, Ahmad S, Khan Z, et al. Candida auris candidemia in Kuwait, 2014. Emerg Infect Dis. 2015;21:1091–1092.
  • Mohsin J, Hagen F, Al-Balushi ZAM, et al. The first cases of Candida auris candidaemia in Oman. Mycoses. 2017;60:569–575.
  • Chowdhary A, Sharma C, Duggal S, et al. New clonal strain of Candida auris, Delhi, India. Emerg Infect Dis. 2013;19:1670–1673.
  • Chowdhary A, Anil Kumar V, Sharma C, et al. Multidrug-resistant endemic clonal strain of Candida auris in India. Eur J Clin Microbiol Infect Dis. 2014;33:919–926.
  • Chakrabarti A, Sood P, Rudramurthy SM, et al. Incidence, characteristics and outcome of ICU-acquired candidemia in India. Intensive Care Med. 2015;41:285–295.
  • Kathuria S, Singh PK, Sharma C, et al. Multidrug-resistant Candida auris misidentified as Candida haemulonii: characterization by matrix-assisted laser desorption ionization-time of flight mass spectrometry and DNA sequencing and its antifungal susceptibility profile variability by vitek 2, CLSI broth microdilution, and etest method. J Clin Microbiol. 2015;53:1823–1830.
  • Magobo R, Corcoran C, Seetharam S, et al. Candida auris –associated candidemia, South Africa. Emerg Infect Dis. 2014;20:1250–1251.
  • Calvo B, Melo ASA, Perozo-Mena A, et al. First report of Candida auris in America: clinical and microbiological aspects of 18 episodes of candidemia. J Infect. 2016;73,:369–374.
  • Morales-López SE, Parra-Giraldo CM, Ceballos-Garzón A, et al. Invasive infections with multidrug-resistant yeast Candida auris, Colombia. Emerg Infect Dis. 2017;23:162–164.
  • Araúz AB, Caceres DH, Santiago E, et al. Isolation of Candida auris from 9 patients in Central America: importance of accurate diagnosis and susceptibility testing. Mycoses. 2018;61:44–47.
  • Ruiz-Gaitán AC, Cantón E, Fernández-Rivero ME, et al. Outbreak of Candida auris in Spain: A comparison of antifungal activity by three methods with published data. Int J Antimicrob Agents. 2019;53(5):541–546.
  • Larkin E, Hager C, Chandra J, et al. The emerging pathogen Candida auris: growth phenotype, virulence factors, activity of antifungals, and effect of SCY-078, a novel glucan synthesis inhibitor, on growth morphology and biofilm formation. Antimicrob Agents Chemother. 2017;61:e02396–16.
  • Borman AM, Szekely A, Johnson EM. Isolates of the emerging pathogen Candida auris present in the UK have several geographic origins. Med Mycol. 2017;55:563–567.
  • Schelenz S, Hagen F, Rhodes JL, et al. First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrob Resist Infect Control. 2016;5:35.
  • Vallabhaneni S, Kallen A, Tsay S, et al. Investigation of the first seven reported cases of Candida auris, a globally emerging invasive, multidrug-resistant fungus-United States, May 2013-August 2016. Am J Transplant. 2017;17:296–299.
  • Schwartz I, Hammond G. First reported case of multidrug-resistant Candida auris in Canada. Canada Commun Dis Rep. 2017;43:150–153.
  • Biswal M, Rudramurthy SM, Jain N, et al. Controlling a possible outbreak of Candida auris infection: lessons learnt from multiple interventions. J Hosp Infect. 2017;97:363–370.
  • Centers for Disease Control and Prevention (CDC). Tracking Candida auris. [Cited 2019 Dec 19]; Available from: https://www.cdc.gov/fungal/candida-auris/tracking-c-auris.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Ffungal%2Fdiseases%2Fcandidiasis%2Ftracking-c-auris.html#world.
  • Kohlenberg A, Struelens MJ, Monnet DL, et al. Candida auris: epidemiological situation, laboratory capacity and preparedness in European Union and European economic area countries, 2013 to 2017. Eurosurveillance. 2018;23. DOI:10.2807/1560-7917.ES.2018.23.13.18-00136.
  • Centers for Disease Control and Prevention (CDC), National Notifiable Disease Surveillance System (NNDSS). Standardized Case Definition for Candida auris clinical and colonization/screening cases and National Notification of C. auris. [Cited 2019 Dec 19]. Available from: https://wwwn.cdc.gov/nndss/conditions/candida-auris/case-definition/2019/
  • Zhu Y, O’Brien B, Leach L, et al. Laboratory Analysis of an Outbreak of Candida auris in New York from 2016 to 2018-Impact and Lessons Learned. J Clin Microbiol. 2019;58:e01503–19.
  • Indian Council of Medical Research. Candida auris in healthcare settings-India. [Cited 2019 Oct 21]. Available from: https://www.icmr.nic.in/sites/default/files/guidelines/candida_Auris.pdf
  • Fakhim H, Vaezi A, Dannaoui E, et al. Comparative virulence of Candida auris with Candida haemulonii, Candida glabrata and Candida albicans in a murine model. Mycoses. 2018;61:377–382.
  • Chatterjee S, Alampalli SV, Nageshan RK, et al. Draft genome of a commonly misdiagnosed multidrug resistant pathogen Candida auris. BMC Genomics. 2015;16:686.
  • Wang X, Bing J, Zheng Q, et al. The first isolate of Candida auris in China: clinical and biological aspects article. Emerg Microbes Infect. 2018;7:93.
  • Rossato L, Colombo AL. Candida auris: what have we learned about its mechanisms of pathogenicity? Front Microbiol. 2018;Vol. 9. Frontiers Media S.A. DOI:10.3389/fmicb.2018.03081
  • Casadevall A, Kontoyiannis DP, Robert V. On the emergence of Candida auris: climate change, azoles, swamps, and birds. MBio. 2019;10:e01397–19. .
  • Borman AM, Szekely A, Johnson EM. Comparative pathogenicity of United Kingdom isolates of the emerging. MSphere. 2016;1:4–6.
  • Sherry L, Ramage G, Kean R, et al. Biofilm-forming capability of highly virulent, multidrug-resistant Candida auris. Emerg Infect Dis. 2017;23:328–331.
  • Kean R, Delaney C, Sherry L, et al. Transcriptome assembly and profiling of Candida auris reveals novel insights into biofilm-mediated resistance. MSphere. 2018;3:e00334–18.
  • Dominguez EG, Zarnowski R, Choy HL, et al. Conserved role for biofilm matrix polysaccharides in Candida auris drug resistance. MSphere. 2019;4:e00680–18.
  • Kean R, McKloud E, Townsend EM, et al. The comparative efficacy of antiseptics against Candida auris biofilms. Int J Antimicrob Agents. 2018;52:673–677.
  • Mayer FL, Wilson D, Hube B. Candida albicans pathogenicity mechanisms. Virulence. 2013;4:119–128.
  • Hornby JM, Jensen EC, Lisec AD, et al. Quorum sensing in the dimorphic fungus Candida albicans is mediated by farnesol. Appl Environ Microbiol. 2001;67:2982–2992.
  • Semreen MH, Soliman SSM, Saeed BQ, et al. Metabolic profiling of Candida auris, a newly-emerging multi-drug resistant Candida species, by GC-MS. Molecules. 2019;24:399.
  • Yue H, Bing J, Zheng Q, et al. Filamentation in Candida auris, an emerging fungal pathogen of humans: passage through the mammalian body induces a heritable phenotypic switch. Emerg Microbes Infect. 2018;7:1–13.
  • Kim SH, Iyer KR, Pardeshi L, et al. Genetic Analysis of Candida auris implicates Hsp90 in morphogenesis and azole tolerance and Cdr1 in azole resistance. MBio. 2019;10:e02529–18.
  • Muñoz JF, Gade L, Chow NA, et al. Genomic insights into multidrug-resistance, mating and virulence in Candida auris and related emerging species. Nat Commun. 2018;9:5346.
  • Bentz ML, Joseph Sexton D, Welsh RM, et al. Phenotypic switching in newly emerged multidrug-resistant pathogen Candida auris. Med Mycol. 2019;57:636–638.
  • Branzk N, Lubojemska A, Hardison SE, et al. Neutrophils sense microbe size and selectively release neutrophil extracellular traps in response to large pathogens. Nat Immunol. 2014;15:1017–1025.
  • Johnson CJ, Davis JM, Huttenlocher A, et al. Emerging fungal pathogen Candida auris evades neutrophil attack. MBio. 2018;9:e02120–18.
  • Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013;13:s.
  • Bruno M, Jaeger M, Kruppa MG, et al. Candida auris: understanding the mechanisms of host immune response. Aspergillus & Aspergillosis Website. [cited 2020 Mar 19]. https://www.aspergillus.org.uk/conference_abstracts/candida-auris-understanding-mechanisms-host-immune-response
  • Navarro-Arias MJ, Hernández-Chávez MJ, García-Carnero LC, et al. Differential recognition of Candida tropicalis, Candida guilliermondii, Candida krusei, and Candida auris by human innate immune cells. Infect Drug Resist. 2019;12:783–794.
  • Sharma C, Kumar N, Pandey R, et al. Whole genome sequencing of emerging multidrug resistant Candida auris isolates in India demonstrates low genetic variation. New Microbes New Infect. 2016;13:77–82.
  • Calcagno AM, Bignell E, Warn P, et al. Candida glabrata STE12 is required for wild-type levels of virulence and nitrogen starvation induced filamentation. Mol Microbiol. 2003;50:1309–1318.
  • Qu X, Yu B, Liu J, et al. MADS-box transcription factor SsMADS is involved in regulating growth and virulence in Sclerotinia sclerotiorum. Int J Mol Sci. 2014;15:8049–8062.
  • Calderone RA, Fonzi WA. Virulence factors of Candida albicans. Trends Microbiol. 2001;9:327–335.
  • Calera JA, Choi GH, Calderone RA. Identification of a putative histidine kinase two-component phosphorelay gene (CaHK1) in Candida albicans. Yeast. 1998;14:665–674.
  • Alonso-Monge R, Navarro-García F, Molero G, et al. Role of the mitogen-activated protein kinase hog1p in morphogenesis and virulence of Candida albicans. J Bacteriol. 1999;181:3058–3068.
  • Day AM, McNiff MM, da Silva Dantas A, et al. Hog1 regulates stress tolerance and virulence in the emerging fungal pathogen Candida auris. MSphere. 2018;3:e00506–18.
  • Reuß O, Morschhäuser J. A family of oligopeptide transporters is required for growth of Candida albicans on proteins. Mol Microbiol. 2006;60:795–812.
  • Rudramurthy SM, Chakrabarti A, Paul RA, et al. Candida auris candidaemia in Indian ICUs: analysis of risk factors. J Antimicrob Chemother. 2017;72:1794–1801.
  • Shastri PS, Shankarnarayan SA, Oberoi J, et al. Candida auris candidaemia in an intensive care unit – prospective observational study to evaluate epidemiology, risk factors, and outcome. J Crit Care. 2020;57:42–48.
  • Van Schalkwyk E, Mpembe RS, Thomas J, et al. Epidemiologic shift in Candidemia driven by Candida auris, South Africa, 2016-2017. Emerg Infect Dis. 2019;25:1698–1707.
  • Jeffery-Smith A, Taori SK, Schelenz S, et al. Candida auris: a Review of the Literature. Clin Microbiol Rev. 2018;31:e00029–17.
  • Weber DJ, Sickbert-Bennett EE, Kanamori H, et al. New and emerging infectious diseases (Ebola, Middle Eastern respiratory syndrome coronavirus, carbapenem-resistant Enterobacteriaceae, Candida auris): focus on environmental survival and germicide susceptibility. Am J Infect Control. 2019;47:A29–38.
  • Cortegiani A, Misseri G, Giarratano A, et al. The global challenge of Candida auris in the intensive care unit. Crit Care. 2019;23:150.
  • Nett JE. Candida auris: an emerging pathogen “incognito”? PLOS Pathog. 2019;15:e1007638.
  • Eyre DW, Sheppard AE, Madder H, et al. A Candida auris outbreak and its control in an intensive care setting. N Engl J Med. 2018;379:1322–1331.
  • Navalkele BD, Revankar S, Chandrasekar P. Candida auris: a worrisome, globally emerging pathogen. Expert Rev Anti Infect Ther. 2017;15:819–827.
  • Piedrahita CT, Cadnum JL, Jencson AL, et al. Environmental Surfaces in healthcare facilities are a potential source for transmission of Candida auris and other Candida species. Infect Control Hosp Epidemiol. 2017;38:1107–1109.
  • Welsh RM, Bentz ML, Shams A, et al. Survival, persistence, and isolation of the emerging multidrug-resistant pathogenic yeast Candida auris on a plastic health care surface. J Clin Microbiol. 2017;55:2996–3005.
  • Madder H, Moir I, Moroney R, et al. Multiuse patient monitoring equipment as a risk factor for acquisition of Candida auris. BioRxiv. 2017;149054. DOI:10.1101/149054.
  • Heaney H, Laing J, Paterson L, et al. The environmental stress sensitivities of pathogenic Candida species, including Candida auris, and implications for their spread in the hospital setting, [published online ahead of print, 2020 Jan 7]. Med Mycol. 2020;1–12.
  • Ekowati Y, Ferrero G, Kennedy MD, et al. Potential transmission pathways of clinically relevant fungi in indoor swimming pool facilities. Int J Hyg Environ Health. 2018;221:1107–1115.
  • Adams E, Quinn M, Tsay S, et al. Candida auris in healthcare facilities, New York, USA, 2013–2017. Emerg Infect Dis. 2018;24:1816–1824.
  • Azar MM, Turbett SE, Fishman JA, et al. Donor-derived transmission of Candida auris during lung transplantation. Clin Infect Dis. 2017;65(6):1040–1042.
  • Sexton DJ, Kordalewska M, Bentz ML, et al. Direct detection of emergent fungal pathogen Candida auris in clinical skin swabs by SYBR green-based quantitative PCR assay. J Clin Microbiol. 2018;56(12):e01337–18.
  • Jackson BR, Chow N, Forsberg K, et al. On the origins of a species: what might explain the rise of Candida auris? J Fungi. 2019;5:58.
  • Centers for Disease Control and Prevention (CDC). Infection Prevention and Control for Candida auris. [Cited 2019 Dec 20]. Available from: https://www.cdc.gov/fungal/candida-auris/c-auris-infection-control.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Ffungal%2Fdiseases%2Fcandidiasis%2Fc-auris-infection-control.html
  • Kenters N, Kiernan M, Chowdhary A, et al. Control of Candida auris in healthcare institutions: outcome of an International Society for Antimicrobial Chemotherapy expert meeting. Int J Antimicrob Agents. 2019;54:400–406.
  • Chow NA, De Groot T, Badali H, et al. Potential fifth clade of Candida auris, Iran, 2018. Emerg Infect Dis. 2019;25:1780–1781.
  • Rhodes J, Abdolrasouli A, Farrer RA, et al. Genomic epidemiology of the UK outbreak of the emerging human fungal pathogen Candida auris. Emerg Microbes Infect. 2018;7:1–12.
  • Chow NA, Muñoz JF, Gade L, et al. Tracing the evolutionary history and global expansion of Candida auris using population genomic analyses. BioRxiv. 2020;896548. DOI:10.1101/2020.01.06.896548.
  • Heath CH, Dyer JR, Pang S, et al. Candida auris sternal osteomyelitis in a man from Kenya visiting Australia, 2015. Emerg Infect Dis. 2019;25:192–194.
  • Chew SM, Sweeney N, Kidd SE, et al. Candida auris arriving on our shores: an Australian microbiology laboratory’s experience. Pathology. 2019;51:431–433.
  • Hamprecht A, Barber AE, Mellinghoff SC, et al. Candida auris in Germany and previous exposure to foreign healthcare. Emerg Infect Dis. 2019;25:1763–1765.
  • Chow NA, Gade L, Tsay SV, et al. Multiple introductions and subsequent transmission of multidrug-resistant Candida auris in the USA: a molecular epidemiological survey. Lancet Infect Dis. 2018;18:1377–1384.
  • Kwon YJ, Shin JH, Byun SA, et al. Candida auris clinical isolates from South Korea: identification, antifungal susceptibility, and genotyping. J Clin Microbiol. 2018;57:e01624–18.
  • Osei Sekyere J. Erratum to: candida auris : A systematic review and meta-analysis of current updates on an emerging multidrug-resistant pathogen. Microbiology open. 2019;8:e00901.
  • Welsh RM, Sexton DJ, Forsberg K, et al. Insights into the unique nature of the east asian clade of the emerging pathogenic yeast Candida auris. J Clin Microbiol. 2019;57:e01624–18.
  • Szekely A, Borman AM, Johnsona EM. Candida auris isolates of the southern asian and south african lineages exhibit different phenotypic and antifungal susceptibility profiles in vitro. J Clin Microbiol. 2019;57:e02055–18. .
  • Escandón P, Chow NA, Caceres DH, et al. Molecular epidemiology of Candida auris in Colombia reveals a highly related, countrywide colonization with regional patterns in amphotericin b resistance. Clin Infect Dis. 2018;68:15–21.
  • Wasi M, Khandelwal NK, Moorhouse AJ, et al. ABC Transporter genes show upregulated expression in drug-resistant clinical isolates of Candida auris: a genome-wide characterization of ATP-Binding Cassette (ABC) Transporter Genes. Front Microbiol. 2019;10:1445.
  • Rybak JM, Doorley LA, Nishimoto AT, et al. Abrogation of triazole resistance upon deletion of CDR1 in a clinical isolate of Candida auris. Antimicrob Agents Chemother. 2019;63:e00057–19.
  • Healey KR, Kordalewska M, Ortigosa CJ, et al. Limited ERG11 mutations identified in isolates of candida auris directly contribute to reduced azole susceptibility. Antimicrob Agents Chemother. 2018;62:e01427–18.
  • Chowdhary A, Prakash A, Sharma C, et al. A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009–17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance. J Antimicrob Chemother. 2018;73(4):891–899.
  • Chaabane F, Graf A, Jequier L, et al. Review on antifungal resistance mechanisms in the emerging pathogen Candida auris. Front Microbiol. 2019;10:2788.
  • Bhattacharya S, Holowka T, Orner EP, et al. Gene duplication associated with increased fluconazole tolerance in Candida auris cells of advanced generational age. Sci Rep. 2019;9:5052.
  • Berkow EL, Lockhart SR. Activity of CD101, a long-acting echinocandin, against clinical isolates of Candida auris. Diagn Microbiol Infect Dis. 2018;90:196–197.
  • Forsberg K, Woodworth K, Walters M, et al. Candida auris : the recent emergence of a multidrug-resistant fungal pathogen. Med Mycol. 2019;57:1–12.
  • Centers for Disease Control and Prevention (CDC). Antifungal Susceptibility Testing and Interpretation- Candida auris. [cited 2019 Dec 7]. Available from: https://www.cdc.gov/fungal/candida-auris/c-auris-antifungal.html
  • Kordalewska M, Lee A, Park S, et al. Understanding echinocandin resistance in the emerging pathogen Candida auris. Antimicrob Agents Chemother. 2018;62:e00238–18.
  • Sarma S, Upadhyay S. Current perspective on emergence, diagnosis and drug resistance in Candida auris. Infect Drug Resist. 2017;10:155–165.
  • Espinel-Ingroff A, Arendrup MC, Pfaller MA, et al. Interlaboratory variability of caspofungin MICs for Candida spp. using CLSI and EUCAST methods: should the clinical laboratory Be testing this agent? Antimicrob Agents Chemother. 2013;57:5836–5842.
  • Kumar JA, Cadnum JL, Jencson AL, et al. Are reduced concentrations of chlorine-based disinfectants effective against Candida auris? Am J Infect Control. 2019;S0196-6553:30808–30809.
  • Ku TSN, Walraven CJ, Lee SA. Candida auris: disinfectants and implications for infection control. Front Microbiol. 2018;9:726.
  • Indian council of medical research. Candida auris in healthcare settings- India. [ Accessd 20 Dec 2019]. Available from: https://www.icmr.nic.in/sites/default/files/guidelines/candida_Auris.pdf
  • GOV.UK. Candida auris: laboratory investigation, management and infection prevention and control. [Cited 2019 Dec 10]. Available from: https://www.gov.uk/government/publications/candida-auris-laboratory-investigation-management-and-infection-prevention-and-control

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.